Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab (MabThera) plus plasma exchange in acute thrombotic thrombocytopenic purpura
2005-002274-30Phase 2Completed
- Sponsor
- University College London
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by University College London. Primary endpoint: Time to remission. Started Nov 2005; status: completed.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2005-002274-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002274-30.